Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633551 | 0.84 | LMNA (0.44) | LMNAPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL22946085 | 0.80 | TSHR (0.36) | LMNAALDH1A1KDM4ETSHRGAA | |
| SCHEMBL29633534 | 0.76 | LMNA (0.58) | LMNAPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL22946244 | 0.76 | LMNA (0.58) | LMNAPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL2962020 | 0.75 | ALDH1A1 (0.50) | LMNAPOLBALDH1A1KDM4EMAPT | |
| SCHEMBL24488926 | 0.74 | POLB (0.35) | LMNAPOLBALDH1A1KDM4ERECQL | |
| SCHEMBL18318930 | 0.74 | LMNA (0.47) | LMNAPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL16056064 | 0.72 | ALDH1A1 (0.51) | LMNAPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL16055280 | 0.72 | SSTR5 (0.40) | LMNAPOLBALDH1A1MAPT | |
| SCHEMBL4879750 | 0.71 | LMNA (0.47) | LMNAALDH1A1KDM4ETSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| CN-119823001-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| CN-114206832-B | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-04 | — | — | CN | disclosed |
| CN-114206832-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | LMNA 2200/4885POLB 4112/4885ALDH1A1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.